INS and type 1 diabetes mellitus: In a preliminary small study of 10 newly diagnosed T1D individuals, semaglutide eliminated the need for mealtime insulin doses among the entire study cohort and allowed 70% to stop basal insulin within 6 months, with the mean HbA1c decreasing from 11.7% at baseline to 5.9% at 6 months and 5.7% at 12 months.112